MARKET

PTCT

PTCT

PTC Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

40.34
-3.08
-7.09%
After Hours: 40.34 0 0.00% 16:56 03/27 EDT
OPEN
41.84
PREV CLOSE
43.42
HIGH
43.16
LOW
40.09
VOLUME
672.30K
TURNOVER
--
52 WEEK HIGH
59.89
52 WEEK LOW
30.79
MARKET CAP
2.53B
P/E (TTM)
-9.2676
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PTCT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PTCT stock price target is 61.00 with a high estimate of 86.00 and a low estimate of 45.00.

EPS

PTCT News

More
  • Do Hedge Funds Love PTC Therapeutics, Inc. (PTCT)?
  • Insider Monkey · 14h ago
  • Edited Transcript of PTCT earnings conference call or presentation 2-Mar-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 4d ago
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • PTC Therapeutics operating chief bids adieu
  • seekingalpha · 03/16 18:40

Industry

Biotechnology & Medical Research
-2.44%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About PTCT

PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.
More

Webull offers kinds of PTC Therapeutics, Inc. stock information, including NASDAQ:PTCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCT stock news, and many more online research tools to help you make informed decisions.